Connect with us


Study Shows Organovo’s Drug Dramatically Reduces Liver Fat in NASH, According to ET HealthWorld



Organovo's drug significantly reduces liver fat in NASH study, ET HealthWorld

London: Organovo Holdings’ experimental drug, FXR314, showed promising results in reducing liver fat in patients with non-alcoholic steatohepatitis (NASH). The mid-stage study reported a reduction in liver fat by as much as 22.8%, sparking optimism in the potential of the drug to enter the multi-billion dollar NASH treatment market. The small biotech firm’s shares surged by 44% to $1.45 following the data release.

NASH, previously known as metabolic function-associated steatohepatitis (MASH), is characterized by an accumulation of fat in the liver, leading to inflammation and scarring. The global market for NASH treatments is projected to exceed $16 billion by 2030, according to Vision Research Reports. Last month, the U.S. health regulator approved Madrigal Pharmaceuticals’ Rezdiffra as the first treatment for this condition.

In a 16-week study involving 214 patients, those who received 3 mg of FXR314 saw an average 22.8% reduction in liver fat, compared to 6.1% in the placebo group. Organovo stated that the drug also improved liver function without exacerbating scarring or fibrosis, and was well-tolerated by patients. Detailed findings of the study are expected to be presented at an upcoming conference.

The positive outcome of the FXR314 study has raised hopes for a potential breakthrough in NASH treatment, addressing a critical medical need for patients with this liver disease. Organovo’s successful mid-stage trial marks a significant advancement in the field of liver health research, with implications for future drug development and patient care.

Click to comment

You must be logged in to post a comment Login

Leave a Reply